Estrogen and TCDD influence RLN2 gene activity in estrogen receptor-positive human breast cancer cells

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 367-373

  Kietz, Silke ^a   Feng, Shu ^b   Agoulnik, Alexander ^b   Hombach Klonisch, Sabine ^c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Arylhydrocarbon receptor (AhR); Breast cancer; Estrogen; MCF 7; Relaxin promoter; RLN2; T47D; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; RELAXIN;

BREAST CANCER; CHROMATIN IMMUNOPRECIPITATION; CONFERENCE PAPER; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RLN1 GENE; RLN2 GENE;

EID: 64549123933     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.03836.x     Document Type: Conference Paper

References (24)

1. Tashima, L.S., G. Mazoujian & G.D. Bryant-Greenwood. 1994. Human relaxins in normal, benign and neoplastic breast tissue. J. Mol. Endocrinol. 12: 351-364.
2. Binder, C., T. Hagemann, B. Husen, et al. 2002. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol. Hum. Reprod. 8: 789-796.
3. Silvertown, J.D., B.J. Geddes & A.J. Summerlee. 2003. Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 144: 3683-3691.
4. Silvertown, J.D., J. Ng, T. Sato, et al. 2006. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int. J. Cancer 118: 62-73.
5. Hombach-Klonisch, S., J. Bialek, B. Trojanowicz, et al. 2006. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am. J. Pathol. 169: 617-632.
6. Feng, S. 2007. Relaxin promotes prostate cancer progression. Clin. Cancer Res. 13: 1695-1702.
7. Binder, C. 2004. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res. Treat. 87: 157-166.
8. Birnbaum, L.S. 1994. The mechanism of dioxin toxicity: Relationship to risk assessment. Environ. Health Perspect. 102 (Suppl. 9): 157-167.
9. Birnbaum, L.S. 1995. Developmental effects of dioxins and related endocrine disrupting chemicals. Toxicol. Lett. 82-83: 743-750.
10. Reyes, H., S. Reisz-Porszasz & O. Hankinson. 1992. Identification of the Ah receptor nuclear translo-cator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256: 1193-1195.
11. Wang, W., R. Smith III & S. Safe. 1998. Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: Modulation of hormone-induced cell cycle enzymes. Arch. Biochem. Biophys. 356: 239-248.
12. Matthews, J. & J.A. Gustafsson. 2006. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl. Recept. Signal. 4: e016.
13. Safe, S., M. Wormke & I. Samudio. 2000. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J. Mammary Gland Biol. Neoplasia 5: 295-306.
14. Rattenborg, T., I. Gjermandsen & E.C. Bonefeld-Jorgensen. 2002. Inhibition of E2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Res. 4: R12.
15. Bowen, W.P. 2000. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 28: 781-788.
16. Jaber, B.M. 2006. The pure estrogen receptor antagonist ICI 182,780 promotes a novel interaction of estrogen receptor-alpha with the 3',5'-cyclic adenosine monophosphate response element-binding protein-binding protein/p300 coactivators. Mol. Endocrinol. 20:2695-2710.
17. Creighton, C.J., K.E. Cordero, J.M. Larios, et al. 2006. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 7: R28.
18. Xu, J., S. Fan & E.M. Rosen. 2005. Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology 146: 2031-2047.
19. Garibay-Tupas, J.L., K.J. Okazaki, L.S. Toshima, et al. 2004. Regulation of the human relaxin genes H1 and H2 by steroid hormones. Mol. Cell. Endocrinol. 219: 115-125.
20. Ohtake, F., A. Baba, I. Takada, et al. 2007. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-566.
21. Pocar, P., B. Fischer, T. Klonisch, et al. 2005. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 129: 379-389.
22. Klinge, C.M., J.L. Bowers, P.C. Kulakosky, et al. 1999. The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements. Mol. Cell. Endocrinol. 157: 105-119.
23. Ricci, M.S., D.G. Toscano & W.A. Toscano, Jr. 1999. ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function. In Vitro Cell Dev. Biol. Anim. 35: 183-189.
24. Ohtake, F., K. Takeyama, T. Matsumoto, et al. 2003. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550.